Berlin I, Deray G, Maistre G, Masson F, Barthelemy C, Legrand J C, Jacobs C
Department of Clinical Pharmacology, Hôpital Pitiè-Salpêtrière, Paris, France.
Eur J Clin Pharmacol. 1990;39(6):593-4. doi: 10.1007/BF00316103.
The effect of 50 and 150 mg cicletanine, a new vasodilator antihypertensive, on plasma atrial natriuretic peptide (ANP), cyclic GMP and antidiuretic hormone has been investigated at rest and during standardized exercise, in a double blind cross over study in healthy subjects. Exercise significantly increased in plasma ANP, cyclic GMP and antidiuretic hormone concentrations, and cicletanine did not affect any of them either at rest or during exercise. Since the alpha-1 adrenoceptor blocker prazosine decreases, beta-adrenoceptor blockers increase and the vasodilator cicletanine does not alter the plasma ANP response to exercise, it is suggested that adrenergic receptors may be directly involved in the regulation of ANP secretion.
在一项针对健康受试者的双盲交叉研究中,研究了新型血管舒张性抗高血压药物西氯他宁50毫克和150毫克在静息状态和标准化运动期间对血浆心钠素(ANP)、环磷酸鸟苷(cGMP)和抗利尿激素的影响。运动显著增加了血浆ANP、cGMP和抗利尿激素的浓度,而西氯他宁在静息状态或运动期间对这些指标均无影响。由于α-1肾上腺素能受体阻滞剂哌唑嗪可降低血浆ANP水平,β-肾上腺素能受体阻滞剂可升高血浆ANP水平,而血管舒张剂西氯他宁不会改变运动时血浆ANP的反应,因此提示肾上腺素能受体可能直接参与ANP分泌的调节。